Arabic Arabic English English French French German German
dark

HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India

HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced that its development partner in India, Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Departure of Founder and CEO Heightens Uncertainty for Galapagos

Next Post

Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818

Related Posts
Total
0
Share